DEA’s Marijuana Hearing Draws Scrutiny

Department of Justice building exterior with stone facade and plants

Marijuana prohibition did not stop use. It also built a federal system that kept science in the dark.

Quick Take

The federal government is again moving marijuana toward Schedule III review.^[1]^[2]
Officials say Schedule III would make research easier, but not legalize adult use.^[1]^[3]
The Drug Enforcement Administration has sparked bias concerns by excluding reform groups from the hearing.^[4]
Supporters argue rescheduling could cut taxes and open more medical studies.^[2]^[13]

Why This Hearing Matters

The Drug Enforcement Administration (DEA) will hold a new hearing on whether marijuana should move from Schedule I to Schedule III. The federal government says that change would recognize medical use and ease some research limits, but it would not legalize recreational marijuana or make it available over the counter.^[1]^[3] That gap matters because the fight is no longer only about use. It is about who gets to define the facts.

The hearing follows a long paper trail. In August 2023, the Department of Health and Human Services formally recommended Schedule III after its scientific and medical review.^[2] In April 2024, the Department of Justice moved medical marijuana products regulated by state licenses and Food and Drug Administration-approved products into Schedule III, which created a narrow federal precedent.^[1] Proponents say that step matters because Schedule III carries fewer research barriers than Schedule I.^[8]

Research, Taxes, and Federal Control

Supporters of rescheduling say the biggest payoff is not retail sales. It is research. Brookings reported years ago that Schedule I rules make researchers jump through heavy registration and sourcing hurdles, while Schedule III would lower those barriers for empirical and double-blind studies.^[8] The National Institute on Drug Abuse says the federal classification still shapes what studies can happen and how easily scientists can study cannabis’s effects.^[3] That is why the dispute keeps returning to the same question: what does the public not know because the law keeps slowing down the science?

There is also a money issue. Harvard Law School panel comments noted that Section 280E tax rules do not apply to Schedule III drugs, which could ease the burden on state-licensed marijuana businesses.^[5] That is one reason the policy debate draws both industry support and skepticism. Critics argue the move still leaves marijuana tightly regulated under federal law and does not solve the broader state-federal conflict.^[4]^[12] In practical terms, rescheduling could help businesses, but it would not end the fight over federal control.

Who Gets Heard in the Process

The hearing process has raised the sharpest political concern. NORML reported that the DEA denied participation requests from NORML and other reform groups and instead selected parties that support keeping cannabis in Schedule I.^[4] That decision has fueled claims that the process is tilted before testimony even starts. It also mirrors a broader distrust many Americans on both left and right feel toward federal agencies that appear to protect old rules instead of testing them against new evidence.

The DEA is resisting a prohibitionist group’s request for an agency official to testify about the harms of marijuana during a hearing on the Trump administration’s move to reschedule cannabis that is scheduled to start next week.https://t.co/9TmRZIaoqx

— Veronica (@Veronica2twit1) June 24, 2026

The larger story is not just marijuana policy. It is the long American habit of banning first and studying later. Research sources in the record show that federal restrictions have made cannabis harder to study, even as state laws moved ahead and public use stayed widespread.^[1]^[3]^[5] That disconnect is why this hearing matters beyond the cannabis debate. It shows how federal institutions can fall behind reality, then frame the catch-up as a narrow technical fix.